Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Hits New 12-Month Low – Should You Sell?

Bayer Aktiengesellschaft (OTCMKTS:BAYRY)’s stock price reached a new 52-week low on Wednesday . The stock traded as low as $4.92 and last traded at $4.92, with a volume of 1992218 shares trading hands. The stock had previously closed at $5.03.

Analyst Ratings Changes

Separately, Bank of America upgraded Bayer Aktiengesellschaft from an “underperform” rating to a “neutral” rating in a research report on Friday, September 6th. Five analysts have rated the stock with a hold rating, According to data from MarketBeat, the company presently has a consensus rating of “Hold”.

Bayer Aktiengesellschaft Price Performance

The stock has a market cap of $19.29 billion, a price-to-earnings ratio of -18.88 and a beta of 1.03. The company has a 50 day simple moving average of $5.89 and a 200-day simple moving average of $6.95. The company has a current ratio of 1.32, a quick ratio of 0.81 and a debt-to-equity ratio of 1.19.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last released its earnings results on Tuesday, November 12th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.17 by ($0.10). Bayer Aktiengesellschaft had a negative net margin of 2.02% and a positive return on equity of 16.90%. The firm had revenue of $10.96 billion during the quarter. Research analysts expect that Bayer Aktiengesellschaft will post 1.31 EPS for the current year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.